SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is currently a major focus on social platforms, driven by investor speculation over future supply burns and its evolving regulatory status as a digital commodity. While some community members remain deeply bullish, citing potential for long-term growth and institutional adoption, others are actively debating whether the asset is stagnant or primed for a significant breakout.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending as active traders debate whether recent volatility and chart patterns signal a potential recovery or further downside, with a polarized community split between long-term holders anticipating a bull cycle and skeptics calling for lower support levels. Market discussions remain heavily focused on the interplay between technical momentum, staking rewards, and broader macroeconomic factors impacting alternative assets.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is currently the subject of intense buyout speculation, fueled by the recent FDA grant of a landmark formal evidentiary hearing for its jet lag treatment and the approval of its bipolar medication, Bysanti. While investors are actively debating the impact of management's confrontational FDA strategy and price suppression, the community is closely monitoring the stock for potential acquisition by major pharmaceutical players looking to secure its high-value pipeline.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is experiencing heavy social media activity, with the community polarized between those aggressively accumulating during recent price volatility and skeptics dismissing it as a typical memecoin pump-and-dump cycle. Investors are closely monitoring key metrics like chain holder growth and upcoming token burn events, while sentiment remains highly volatile as the asset navigates broader market consolidation.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is attracting significant attention as investors anticipate key regulatory milestones, specifically an upcoming FDA decision for ivonescimab. While some community members express frustration with recent price volatility and delays, others remain deeply bullish, pointing to strong trial data and a potential short squeeze as major catalysts for future growth.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently a focal point for community speculation as traders monitor shifting institutional sentiment and the emergence of new ecosystem projects. Investors are actively debating potential price movements amidst broader market volatility, with many users focused on staking rewards and identifying early-stage tokens within the network's expanding meme coin landscape.

"What's Updog?" is a Community Led token.

UpDog

The UpDog ($UPDOG) community is driving significant momentum across social channels by leveraging engagement-heavy strategies and meme-focused community building on the Solana blockchain. Investors and community members are actively discussing the project's long-term presence in the market while coordinating efforts to increase awareness and drive adoption through persistent social signaling.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging as investors lean into the deep historical lore of the original 2011 meme, which has transitioned from a Bitcoin-mocking internet joke to an on-chain project on Solana. The community is buzzing over its potential to reach billion-dollar valuations, driven by active engagement, historical memes, and the backing of significant whale interest.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is seeing renewed market attention as traders monitor potential institutional interest and ETF speculation, fueling community debates over whether it can replicate its past breakout momentum. While some participants express frustration with price volatility and the broader memecoin landscape, others view the current consolidation as an accumulation phase in anticipation of a potential market-wide recovery tied to broader crypto sentiment.

Maulcoin

Maulcoin is capturing attention as the community rallies around organic growth and a 'diamond hand' holding strategy to push toward a higher market cap. Enthusiastic investors are actively highlighting its trending status on social platforms and urging others to join the movement before further milestones are reached.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Each Series AA share can convert into 20 common shares, while Series AAA shares can convert into 150.</li><li>Alongside the investment, David E. Lazar has been named Co-Chief Executive Officer and Chairman of the Board.</li><li>The company plans to use the funds raised from the offering to support daily operations, cover severance, and manage general corporate needs.&nbsp;</li></ul>Indaptus Therapeutics Inc. (INDP) announced on Monday that it has secured a $6 million investment through the sale of non-voting convertible preferred stock to investor David E. Lazar.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/INDP">Indaptus’ stock</a> traded over 12% higher. However, on Stocktwits, retail sentiment around the stock changed to ‘bearish’ from ‘extremely bearish’ territory the previous day amid ‘extremely low’ message volume levels.&nbsp;<h2 class="st-heading-2">Transaction Details&nbsp;</h2>The investment, finalized on December 23, includes 300,000 Series AA preferred shares and 700,000 Series AAA preferred shares. Each Series AA share can convert into 20 common shares, while Series AAA shares can convert into 150, pending stockholder approval expected in the first-quarter (Q1) 2026.<blockquote>"In making this significant investment in Indaptus, I look forward to continuing to evaluate the company’s lead product candidate while actively exploring strategic opportunities to drive value for our stockholders.”-David E. Lazar, Investor</blockquote>Alongside the investment, David E. Lazar has been named Co-Chief Executive Officer and Chairman of the Board. Once stockholder approval is received, Lazar can nominate up to three additional directors.<h2 class="st-heading-2">Strategic Implications</h2>The company plans to use the funds raised from the offering to support daily operations, cover severance, manage general corporate and working capital needs, and pay offering-related costs, including securing stockholder approval.Indaptus develops Decoy, a patented, antigen-agnostic immunotherapy using attenuated Gram-negative bacteria to activate innate and adaptive immune responses. Preclinical studies show tumor and viral eradication, enhanced by combinations with checkpoint inhibitors or chemotherapy.Indaptus’ Decoy platform activates and matures multiple human immune cells in vitro, exhibits low toxicity upon intravenous administration, and demonstrates promising single-agent activity against chronic hepatitis B and HIV in preclinical studies.INDP stock has declined by over 90% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/soft-bank-acquires-digital-bridge-for-4-billion-to-scale-ai-infrastructure/cL75v6iREx9">SoftBank Acquires DigitalBridge For $4 Billion To Scale AI Infrastructure</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

Why Did INDP Stock Gain 12% Today?

The company has secured a $6 million investment from investor David E. Lazar via the sale of non-voting convertible preferred stock. 

Equity

The company has secured a $6 million investment from investor David E. Lazar via the sale of non-voting convertible preferred stock. 


What Does the Market Think About Indaptus Therapeutics Inc?

Biotech Stocks To Keep An Eye On - December 24th

Abivax, Indaptus Therapeutics, Danaher, Vertex Pharmaceuticals, Moderna, argenex, and Amicus Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Indaptus Therapeutics, Uipath, Trinity Biotech, Sable Offshore And McDonald's: Why These 5 Stocks Are On Investors' Radars Today

INDP, PATH, TRIB, SOC, MCD were among the stocks seen among investors on Tuesday, Dec. 23, 2025.read more...

Indaptus Therapeutics, Inc. is a clinical biotechnology company. The firm engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.

Current Price	$2.11
Prev Close	$1.85
Open	$1.85
Dividend Yield	0.00%
50-Day Moving Average	$1.84
Beta	1.21
Avg. Volume	44,585.70
PE Ratio	-0.09

52-Week High	$19.91
52-Week Low	$1.51
Market Capitalization	$4.73M
EPS (Annual)	-$21.58
Price to Book	1.46
Revenue Per Employee	$0.00

INDP
Indaptus Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest INDP News

INDPIndaptus Therapeutics Inc